Complex Generics: US FDA, Sponsors View Roadblocks Very Differently

As GDUFA III negotiations continue, FDA doesn’t seem ready to make additional changes to approval process, but industry argues guidance practices and communications need fixing and that consumers are missing out on potential savings because of it.

FDA building
The US FDA approval process for complex generic drugs continues to vex sponsors, who want a more predictable timeline • Source: Shutterstock

ANDA sponsors feel some more tweaking of the assessment process is necessary to speed approval of complex generics, but the US Food and Drug Administration appears more willing to wait for the current process to bear fruit.

In what may be a rare case of indirectly open generic drug user fee reauthorization negotiating, generic sponsors suggested several changes during a 9 February webinar hosted by The Hill...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By 

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 

Generics Bulletin reviews global regulatory developments across the world.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By 

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.

ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth

 
• By 

ANI Pharmaceuticals says it has delivered an “exceptionally strong first quarter,” with total sales reaching over $197m, amid plans to kick off a Phase IV clinical trial for Cortrophin Gel for acute gouty arthritis later this year.

More from Products

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By 

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 

Generics Bulletin reviews global regulatory developments across the world.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By 

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.